Using technetium 99m tetrofosmin parathyroid imaging to detect parthyroid adenoma and its relation to P-glycoprotein expression

Surgery

Volumn 132, Issue 3, 2002, Pages 456-460

  Wu, Hurng Sheng ^a,b,c,d   Liu, Yao Chi ^a,b,c,d   Kao, Albert ^a,b,c,d   Wang, Jhi Joung ^a,b,c,d   Ho, Shung Tai ^a,b,c,d  

^a SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; TETROFOSMIN TC 99M;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PARATHYROID ADENOMA; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 0036748160     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(02)00111-3     Document Type: Article

References (26)

1. Coakley AJ. Parathyroid imaging. Nucl Med Commun 1995;16:522-33.
2. Goris ML, Basso LV, Keeling C. Parathyroid imaging. J Nucl Med 1991;32:887-9.
3. Miller DL, Doppman JL, Shawker TH, Krudy AG, Norton JA, Vucich JJ, et al. Localization of parathyroid adenomas in patients who have undergone surgery. Part 1. Noninvasive imaging methods. Radiology 1987;162:133-7.
4. Greenspan BS, Brown ML, Dillehay GL, McBiles M, Sandler MP, Seabold JE, et al. Procedure guideline for parathyroid scintigraphy. Society of Nuclear Medicine. J Nucl Med 1998;39:1111-4.
5. Baillet GY, Mena IG, Kuperus JH, Robertson JM, French WJ. Simultaneous technetium-99m MIBI angiography and myocardial perfusion imaging. J Nucl Med 1989;30:38-44.
6. O'Doherty MJ, Kettle AG, Wells P, Collins RE, Coakley AJ. Parathyroid imaging with technetium-99m sestamibi: pre-operative localization and tissue uptake studies. J Nucl Med 1992;33:313-8.
7. Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m sestamibi (double-phase study). J Nucl Med 1992;33:1801-7.
8. Higley B, Smith FW, Smith T, Gemmell HG, Das-Gupta P, Gvozdanovic DV, et al. Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry, and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993;34:30-8.
9. Kelly JD, Forster AM, Higley B, Archer CM, Booker FS, Canning LR, et al. Technetium-99m tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 1993;34:222-7.
10. Fjeld JG, Erichsen K, Pfeffer PF, Clausen OP, Rootwelt K. Technetium-99m tetrofosmin for parathyroid scintigraphy: a comparison with sestamibi. J Nucl Med 1997;38:834.
11. Ishibashi M, Nishida H, Hiromatsu Y, Kojima K, Tabuchi E, Hayabuchi N. Comparison of technetium-99m MIBI, technetium-99m tetrofosmin, ultrasound, and MRI for localization of abnormal parathyroid glands. J Nucl Med 1998;39:320-4.
12. Leslie WD, Riese KT, Dupont JO, Peterdy AE. Parathyroid adenomas without sestamibi retention. Clin Nucl Med 1995;20:699-702.
13. Rauth JD, Sessions RB, Shupe SC, Ziessman HA. Comparison of Tc-99m MIBI and TI-201/Tc-99m pertechnetate for diagnosis of primary hyperparathyroidism. Clin Nucl Med 1996;21:602-8.
14. Tabuenca MJ, Vargas JA, Varela A, Salas C, Durantez A, Ortiz Berrocal J. Technetium-99m tetrofosmin scintigraphy, P-glycoprotein, and lung cancer. J Nucl Med 1998;39:1830-1.
15. Crankshaw CL, Marmion M, Luker GD, Rao V, Dahlheimer J, Burleigh BD, et al. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein. J Nucl Med 1998;39:77-86.
16. Bae KT, Piwnica Worms D. Pharmacokinetic modeling of multidrug resistance P-glycoprotein transport of gamma-emitting substrates. QJ Nucl Med 1997;41:101-10.
17. Hendrikse NH, Franssen EJ, van der Graaf WT, Vaalburg W, de Vries EG. Visualization of multidrug resistance in vivo. Eur J Nucl Med 1999;26:283-93.
18. Tabuenca MJ, Vargas JA, Varela A, Salas C, Durantez A, Ortiz Berrocal J. Correlation between 99m Tc-tetrofosmin uptake and P-glycoprotein expression in non-small-cell lung cancer. Rev Esp Med Nucl 1998;17:427-34.
19. Piwnica Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-84.
20. Rao VV, Chiu ML, Kronauge JF, Piwnica Worms D. Expression of recombinant human multidrug-resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m sestamibi. J Nucl Med 1994;35:510-5.
21. Kostakoglu L, Kiratli P, Ruacan S, Hayran M, Emri S, Ergun EL, et al. Association of tumor washout rates and accumulation of technetium-99m MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med 1998;39:228-34.
22. Sun SS, Shiau YC, Lin CC, Kao A, Lee CC. Correlation between P-glycoprotein (Pgp) expression in parathyroid and Tc-99m MIBI parathyroid image findings. Nucl Med Biol 2001;28:929-33.
23. Yang X, Uziely B, Groshen S, Lukas J, Israel V, Russell C, et al. MDR1 gene expression in primary and advanced breast cancer. Lab Invest 1999;79:271-280.
24. Kreisholt J, Sorensen M, Jensen PB, Nielsen BS, Andersen CB, Sehested M. Immunohistochemical detection of DNA topoisomerase II alpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer. Br J Cancer 1998;77:1469-73.
25. Mitchell BK, Cornelius EA, Zoghbi S, Murren JR, Ghoussoub R, Flynn SD, et al. Mechanism of technetium 99m sestamibi parathyroid imaging and the possible role of P-glycoprotein. Surgery 1996;120:1039-45.
26. Axiotis CA, Bani D, Bianchi S, Pioli P, Tanini A, Brandi ML. P-glycoprotein is expressed in parathyroid epithelium and is regulated by calcium. Calcified Tissue Int 1995;56:170-4.